









市場行情
/
股票
/
nasdaq-derm
/

Journey Medical Corp

DERM

8.010USD

+0.140+1.78%

收盤 12/22, 16:00（美東）報價延遲15分鐘

211.24M總市值

虧損本益比TTM



Journey Medical Corp

8.010

+0.140+1.78%

概覽公司財務分析

概覽

公司

財務

分析

關於 Journey Medical Corp 公司

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Journey Medical Corp簡介



公司代碼DERM

公司名稱Journey Medical Corp

上市日期Nov 12, 2021

CEOMaraoui (Claude)

員工數量41

證券類型Ordinary Share

年結日Nov 12

公司地址9237 E Via De Ventura Blvd., Suite 105

城市SCOTTSDALE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編85258

電話14804346670

網址https://journeymedicalcorp.com/

公司代碼DERM

上市日期Nov 12, 2021

CEOMaraoui (Claude)

Journey Medical Corp公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Claude Maraoui

President, Chief Executive Officer, Director

2.06M

+150.79%

Dr. Lindsay A. Rosenwald, M.D.

Executive Chairman of the Board

377.89K

+15.25%

Mr. Ramsey Alloush

Chief Operating Officer, General Counsel

316.68K

+17.37%

Mr. Joseph Benesch, CPA

Chief Financial Officer, Corporate Controller

100.78K

+40.22%

Mr. Neil Herskowitz

Independent Director

98.89K

+25.35%

Ms. Miranda Jayne Toledano

Independent Director

98.89K

+25.35%

Mr. Michael C. Pearce

Independent Director

57.17K

+53.80%

Ms. Jaclyn Jaffe

Investor Relations

Mr. Justin Smith

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Claude Maraoui

President, Chief Executive Officer, Director

2.06M

+150.79%

Dr. Lindsay A. Rosenwald, M.D.

Executive Chairman of the Board

377.89K

+15.25%

Mr. Ramsey Alloush

Chief Operating Officer, General Counsel

316.68K

+17.37%

Mr. Joseph Benesch, CPA

Chief Financial Officer, Corporate Controller

100.78K

+40.22%

Mr. Neil Herskowitz

Independent Director

98.89K

+25.35%

Ms. Miranda Jayne Toledano

Independent Director

98.89K

+25.35%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

業務USD

名稱

營收

佔比

Qbrexa

6.95M

46.30%

Accutane

3.40M

22.62%

Emrosi

2.79M

18.62%

Amzeeq

879.00K

5.86%

Other branded revenue

735.00K

4.90%

Zilxi

256.00K

1.71%

地區USD

名稱

營收

佔比

United States

15.01M

100.00%

業務

地區

業務USD

名稱

營收

佔比

Qbrexa

6.95M

46.30%

Accutane

3.40M

22.62%

Emrosi

2.79M

18.62%

Amzeeq

879.00K

5.86%

Other branded revenue

735.00K

4.90%

Zilxi

256.00K

1.71%

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

Fortress Biotech Inc

15.90%

Maraoui (Claude)

9.75%

Tang Capital Management, LLC

8.77%

Wasatch Global Investors Inc

6.18%

Opaleye Management Inc.

4.59%

其他

54.80%

持股股東

佔比

Fortress Biotech Inc

15.90%

Maraoui (Claude)

9.75%

Tang Capital Management, LLC

8.77%

Wasatch Global Investors Inc

6.18%

Opaleye Management Inc.

4.59%

其他

54.80%

股東類型

持股股東

佔比

Corporation

15.90%

Individual Investor

15.49%

Hedge Fund

14.72%

Investment Advisor

12.26%

Investment Advisor/Hedge Fund

11.73%

Private Equity

1.08%

Insurance Company

0.85%

Research Firm

0.40%

Pension Fund

0.20%

其他

27.36%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

111

6.92M

29.29%

2025Q3

113

6.92M

33.12%

+300.88K

2025Q2

111

6.62M

36.44%

+1.49M

2025Q1

5.12M

29.92%

+3.29K

2024Q4

3.80M

30.46%

+100.75K

2024Q3

2.18M

26.36%

-187.63K

2024Q2

2.37M

22.85%

+547.02K

2024Q1

1.83M

18.72%

-778.53K

2023Q4

1.36M

20.20%

-795.63K

2023Q3

2.15M

17.23%

+484.38K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fortress Biotech Inc

3.36M

16.55%

Apr 14, 2025

Maraoui (Claude)

2.06M

10.15%

+1.24M

+150.79%

Aug 25, 2025

Tang Capital Management, LLC

1.85M

9.13%

Jun 30, 2025

Wasatch Global Investors Inc

1.15M

5.67%

+221.46K

+23.80%

Jun 30, 2025

The Vanguard Group, Inc.

564.99K

2.78%

+192.73K

+51.77%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

480.30K

2.36%

+437.14K

+1012.83%

Jun 30, 2025

Rosenwald (Lindsay A)

377.89K

1.86%

+50.00K

+15.25%

Aug 05, 2025

Essex Investment Management Company, LLC

228.20K

1.12%

+216.74K

+1890.08%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.02%

iShares Russell 2000 Growth ETF

0.01%

Global X Russell 2000 ETF

ProShares Hedge Replication ETF

iShares Russell 2000 ETF

DFA Dimensional US Sustainability Core 1 ETF

Dimensional US Core Equity 1 ETF

ProShares UltraPro Russell2000

Royce Quant Small-Cap Quality Value ETF

Proshares Ultra Russell 2000

iShares Micro-Cap ETF

佔比0.02%

iShares Russell 2000 Growth ETF

佔比0.01%

Global X Russell 2000 ETF

佔比0%

ProShares Hedge Replication ETF

佔比0%

iShares Russell 2000 ETF

佔比0%

DFA Dimensional US Sustainability Core 1 ETF

佔比0%

Dimensional US Core Equity 1 ETF

佔比0%

ProShares UltraPro Russell2000

佔比0%

Royce Quant Small-Cap Quality Value ETF

佔比0%

Proshares Ultra Russell 2000

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Journey Medical Corp的前五大股東是誰？



Journey Medical Corp的前五大股東如下：
Fortress Biotech Inc
持有股份：3.36M
佔總股份比例：16.55%。
Maraoui (Claude)
持有股份：2.06M
佔總股份比例：10.15%。
Tang Capital Management, LLC
持有股份：1.85M
佔總股份比例：9.13%。
Wasatch Global Investors Inc
持有股份：1.15M
佔總股份比例：5.67%。
The Vanguard Group, Inc.
持有股份：564.99K
佔總股份比例：2.78%。